In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

ESC Congress 2017 Hot Line LBCT Programme

The most anticipated cardiovascular science in the world

Sophia Antipolis, 20 July 2017: The highly anticipated ESC Congress 2017 Hot Line Late Breaking Science programme is set to reveal the latest and most exciting discoveries in all fields of cardiology.

Overall, the number of highly relevant late breaking research results will encompass 40 presentations.

This includes 21 Late Breaking Clinical Trials which will be presented and discussed in Four Hot Line Sessions as well as 12 Late Breaking Registry Results and Clinical Trial Updates, emerging long-term data from major cardiovascular trials whose initial results had already been presented in previous years.

Four Hot Line sessions


Hot Line - Late Breaking Clinical Trials 1 

  • RACE 3: Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure
  • CASTLE-AF: Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation
  • CANTOS: The canakinumab anti-inflammatory thrombosis outcomes study
  • COMPASS: Cardiovascular outcomes for people using anticoagulation strategies: Primary results
  • COMPASS: Results in patients with coronary artery disease and in patients with peripheral artery disease

>Link to session

Hot Line - Late Breaking Clinical Trials 2

  • SPYRAL HTN OFF-MED: Assessment of the efficacy and safety of renal denervation in the absence of antihypertensive medications
  • DETO2X-AMI: Determination of the role of oxygen in suspected acute myocardial infarction
  • EMANATE: Apixaban vs conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion
  • IMPACT-AF: An international multicenter clustered randomized trial to improve treatment with oral anticoagulants in atrial fibrillation
  • THE VIVA trial: The Viborg vascular randomised screening trial
  • ORION 1: Impact of a single or two dose regimen of inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged reductions in LDL-cholesterol over 1 year

>Link to session

Hot Line - Late Breaking Clinical Trials 3

  • PRECISION-ABPM: Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement
  • REVEAL: A naturally randomized trial comparing the effect of genetic variants that mimic CETP inhibitors and statins on the risk of cardiovascular disease
  • SIOVAC: Effect of sildenafil on clinical outcomes in patients with corrected valvular heart disease and residual pulmonary hypertension
  • LAACS: Protection of the brain on occasion of planned open heart surgery by surgical closure of the left atrial appendage
  • CAAM: Airway management during cardiopulmonary resuscitation: Tracheal intubation versus bag valve mask ventilation

>Link to session

Hot Line - Late Breaking Clinical Trials 4

  • HPS3/TIMI55-REVEAL: Clinical effects of anacetrapib in people with established vascular disease
  • EMPATHY: Intensive treat-to-target LDL-C lowering therapy using statins in patients of diabetic retinopathy to reduce cardiovascular events
  • Ex-DHF: Exercise training in diastolic heart failure: a multicenter, prospective, randomized, controlled, parallel group trial
  • The CAPTAF trial: Catheter ablation compared with optimized pharmacological therapy for atrial fibrillation, a randomized multicentre study of quality of life and implantable cardiac monitoring after 12 month follow-up
  • REHEARSE-AF: Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation

>Link to session


Two Clinical Trial Update sessions

Clinical Trial Update 1

  • PATHWAY-2: Mechanisms for the benefit of spironolactone in resistant hypertension
  • FOURIER: Clinical efficacy and safety of achieving very low LDL-cholesterol levels with the PCSK9 inhibitor evolocumab
  • SPRINT: Increased all-cause mortality with intensive blood-pressure control in patients with a baseline systolic blood pressure of >=160 mmHg and a lower Framingham risk score
  • AFFIRM: Systolic blood pressure variability and major adverse outcomes in patients with atrial fibrillation
  • DAPT (Long-term follow-up of NIPPON trial): The long-term efficacy and safety of short dual antiplatelet therapy
  • ALBATROSS: Aldosterone lethal effects blocked in acute myocardial infarction treated with or without reperfusion to improve outcome and survival at six months follow-up

>Link to session

Clinical Trial Update 2

  • PRECISION: Prospective randomized evaluation of celecoxib integrated safety vs. ibuprofen of naproxen
  • GLAGOV: Effect of the PCSK9 inhibitor, evolocumab, on the composition of coronary atherosclerosis
  • FOURIER: Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk
  • EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes after coronary artery bypass graft surgery
  • HOPE 3: Blood pressure levels for initiation of antihypertensive drug therapy and targets of blood pressure lowering in intermediate risk people without cardiovascular disease
  • EARLY BAMI: One year clinical outcome of early administration of intravenous beta blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention.

>Link to session


Two Late Breaking Registry sessions

Hot Line - Late Breaking Registry Results 1

  • PURE: Fruit, vegetable, and legume intake and cardiovascular disease and deaths: The prospective urban rural epidemiology study of 135,000 people in 18 countries
  • Dietary fats are protective but carbohydrates are harmful: First results of the PURE nutrition study on 135,000 people from 18 countries in 5 continents
  • Preexisting chronic kidney disease increases the risk of triggering acute myocardial infarction due to Asian dust exposure
  • HCM-EVIDENCE: An international external validation study of the 2014 European Society of Cardiology Guideline on sudden cardiac death prevention in hypertrophic cardiomyopathy
  • CHANGE DAPT: Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents
  • Pretreatment with P2Y12 receptor antagonists is not associated with improved clinical outcomes in STEMI

>Link to session

Hot Line - Late Breaking Registry Results 2

  • MAUDE: Leaflet thrombosis following transcatheter aortic valve replacement
  • Prevalence of serious complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014
  • Implementation and outcomes in STEMI: Implementation of modern treatments explains improvements in outcomes after ST-Elevation Myocardial Infarction over a 20-year period in Sweden from 1995 to 2014
  • CLARIFY: Can we explain the J curve in hypertensive patients with coronary artery disease, an analysis of 22,672 patients
  • Afinder: Effectiveness of community atrial fibrillation screening in over 10,000 citizens using smartphone electrocardiogram
  • AGES Reykjavik: Fibrosis as measured by the biomarker, tissue inhibitor metalloproteinase 1, predicts mortality in age gene environment susceptibility

>Link to session

New this year Two dedicated Late Breaking Science Moderated Poster Session (Sunday & Monday) will be featuring an additional 14 trials / research and the opportunity to interact directly with the investigators around the poster.

Original science will also be showcased in the different abstract sessions - Advances in Science, Rapid Fire Abstracts, Moderated Posters, Best Posters and traditional posters.


Topics of particular interest to the press will be featured in three Press Conferences on:


  • Cardiac interventions - Expanding applications - Saturday 26 August 15:00-16:00
  • Living longer - Tips and tricks - Sunday 27 August 9:00-10:00
  • Cholesterol lowering - Reality check and new directions - Tuesday 29 August 9:00-10:00

>Link to Press Conference details


Notes to editor

Contact the ESC Press Office
Tel: +33 (0)4 89 87 24 83

Journalists planning to attend are invited to
Get accredited here
Get registered here

Press Material
This year, press releases will be available here when the embargo lifts and under embargo on a USB key and on the Exclusive web page in advance only for on-site press representatives.

No more paper version will be made available on-site but e-printers will be displayed in the Press Working Area.

New embargo rule this year
For Hot Line Studies, Basic and Translational Science, Clinical Trial, Registry Update, Oral and Poster abstract-based presentations: the embargo is lifted at the start of the scientific session in which the concerned presentation/study is scheduled. (No longer at the press conference occurring before the session)

Please consult the ESC Media & Embargo policy: here

About the European Society of Cardiology
The ESC brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.

About ESC Congress 2017
ESC Congress is the world’s largest and most influential cardiovascular scientific conference contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 will take place from 26 to 30 August at the Fira Barcelona in Barcelona, Spain.

The press conference schedule is here

The scientific programme is here